Answers are grounded in this paper and cite their sources.
Neuro–tumor crosstalk is increasingly recognized as a fundamental driver of cancer progression. Calcitonin gene-related peptide (CGRP), a neuropeptide classically associated with sensory neurons, has emerged as a key mediator of tumor growth, immune suppression, and cancer-associated symptoms across multiple malignancies. However, the role of CGRP signaling in cervical cancer remains poorly defined. We comprehensively analyzed CGRP expression and its clinical relevance in cervical cancer using TCGA transcriptomic datasets, gene correlation analyses, and survival models. Single-cell RNA sequencing data were leveraged to define the cellular distribution of the CGRP receptor calcitonin receptor-like receptor (CALCRL). In HUVECs, CALCRL was silenced by siRNA and evaluated using proliferation, tube-formation, gene-expression, rescue, and signaling assays, including exogenous α-CGRP stimulation and VEGFR1/VEGFR2 overexpression. In vivo, CGRP-receptor inhibition was evaluated in SiHa, CaSki, and HeLa xenograft models using Fremanezumab or olcegepant. Elevated CGRP expression was associated with adverse prognosis in TCGA-CESC, and independent clinical validation showed that high CALCB expression was associated with poorer survival (log-rank P = 0.0036). Single-cell transcriptomic analyses consistently revealed that CALCRL expression was highly enriched in endothelial cells. CALCRL silencing impaired endothelial proliferation and angiogenic capacity, whereas exogenous α-CGRP enhanced these phenotypes in control cells but not in CALCRL-silenced cells. VEGFR1 or VEGFR2 overexpression partially rescued the proliferation defect caused by CALCRL depletion. Pharmacological inhibition of CGRP-receptor signaling consistently suppressed tumor growth across SiHa, CaSki, and HeLa xenograft models. These findings provide preclinical evidence that CGRP–CALCRL signaling promotes cervical cancer progression through endothelial angiogenic activity and VEGFR-associated signaling, supporting further investigation of this pathway as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: